Veeva Systems Inc.
VEEVHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Veeva Systems Inc. focuses on Health Information Services services and products. Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company carries a $44.54B market cap, placing it firmly in the large-cap category. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands.
Market Cap
$44.54B
Beta
0.97
P/E (TTM)
45.02
P/E (Fwd)
26.86
EPS (TTM)
$6.11
EPS (Fwd)
$10.24
ROE
14.4%
ROA
7.6%
Cash
$7.24B
Total Debt
$151.7M
Free CF
$1.26B
52W Change
-2.7%
Annual Financials
Cash vs Debt
Where VEEV stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, VEEV finished 53.40% above its 150-day moving average ($186.24) and 43.69% above its 200-day moving average ($198.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VEEV overbought or oversold?
At the September 1, 2026 close, VEEV's RSI(14) was 74.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $7.24B in cash comfortably exceeding the $151.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $1.26B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 14.4% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $2.16B (2023) to $3.20B (2026), reflecting a 48% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VEEV.